Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
IN RE CELGENE CORPORATION, INC. SECURITIES LITIGATION
Case Number:
2:18-cv-04772
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
- Brodsky Smith
- Carella Byrne
- Cohn Lifland
- Dann Law Firm
- Fox Rothschild
- Gibbons PC
- Kantrowitz Goldhamer
- Kessler Topaz
- Levi & Korsinsky
- Lite DePalma
- Saxena White
- Seeger Weiss
Companies
Sectors & Industries:
-
June 26, 2020
Celgene Fights Investors' Class Cert. Bid In Stock-Drop Suit
Celgene Corp. Inc. is urging a New Jersey federal court to reject a Swedish investor's bid to certify a proposed class action claiming the biopharmaceutical company artificially inflated its share price by concealing timeline and growth problems with two of its drugs, arguing that certain alleged misstatements were made after the stock was purchased.
-
May 04, 2020
Celgene Investors Seek Cert. In Suit Over Drug Disclosures
Celgene investors have asked a New Jersey federal judge for class certification in their suit accusing the biopharmaceutical company of artificially inflating its share price by failing to disclose timeline and growth problems with two of its drugs.
-
December 20, 2019
Celgene Can't Shake Shareholder Suit Over Drug Trial
Celgene and several of its executives must face trimmed down securities fraud claims brought against them by investors who say the biotech company hyped up the value of a trial drug for Crohn's disease before pulling the plug, a New Jersey federal judge found Thursday.
-
September 27, 2018
Kessler Topaz Tapped To Lead Celgene Investor Suit
Kessler Topaz Meltzer & Check LLP has taken the helm of a securities class action accusing biotech company Celgene of hyping up the value of a trial drug for Crohn's disease before pulling the plug and causing share prices to plummet, according to an order filed Thursday in New Jersey federal court.